AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best high growth stocks. Bloomberg reported on July 3 that AstraZeneca is engaged ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Citi downgraded Man Group on Wednesday to 'neutral' from 'buy' and slashed its price target on the stock to 185.0p from ...

AstraZeneca PLC closed 22.77% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca PLC closed 23.68% short of its 52-week high of £133.88, which the company achieved on September 3rd.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...